论文部分内容阅读
目的:观察交泰丸加减方对心肾综合征进展期患者心肾功能的改善作用。方法:60例心肾综合征进展期患者根据完全随机设计原则分为治疗组和对照组,在规范的西药治疗基础上,治疗组加用交泰丸加减,疗程14 d,观察气喘、水肿、尿少等主要中医症状、心功能、肾功能变化,评价药物疗效。结果:与对照组比较,治疗组患者治疗后症状总积分明显减少(P<0.05);中医证候改善优于对照组(P<0.05)。与治疗前比较,两组治疗后纽约心脏病协会(NYHA)心功能分级显著改善(P<0.01);治疗组疗后B型脑钠肽前体(NT-proBNP)显著下降(P<0.01),与对照组比较,治疗组NT-proBNP下降显著(P<0.01);与对照组比较,治疗组治疗后尿素氮(BUN)明显下降(P<0.05)。与治疗前比较,两组治疗后血胱氨酸蛋白酶抑制物-C(Cys-C)均明显下降(P<0.05),治疗组下降显著(P<0.01),与对照组比较,治疗组Cys-C下降明显(P<0.05)。结论:交泰丸加减方能改善心肾综合征进展期患者心肾功能恶化。
Objective: To observe the improving effect of Jiaotai Pills on cardiorenal function in patients with advanced cardiorenal syndrome. Methods: Sixty patients with advanced cardio-renal syndrome were divided into treatment group and control group according to a completely randomized design principle. On the basis of standardized western medicine treatment, the treatment group plus Jiaotai pill plus or minus, the course of treatment 14 days, observe the asthma, edema , Less urine and other major symptoms of Chinese medicine, heart function, changes in renal function, evaluation of drug efficacy. Results: Compared with the control group, the total score of symptoms in the treatment group decreased significantly (P <0.05); the improvement of TCM syndromes was better than that in the control group (P <0.05). Compared with those before treatment, the New York Heart Association (NYHA) cardiac function scores were significantly improved (P <0.01) after treatment in both groups; NT-proBNP was significantly decreased in treatment group after treatment (P <0.01) Compared with the control group, NT-proBNP decreased significantly in the treatment group (P <0.01). Compared with the control group, the BUN in the treatment group decreased significantly (P <0.05). Compared with those before treatment, the levels of cystatin C (Cys-C) in both groups were significantly decreased (P <0.05), and the treatment group decreased significantly (P <0.01). Compared with the control group, the Cys -C decreased significantly (P <0.05). Conclusion: Jiaotai Pills can improve heart and kidney function in patients with advanced cardiorenal syndrome.